Related Experiment Video
Updated: Aug 7, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Treatment Strategies in Incident and Recurrent Hyperkalemia: Insights from the TRACK Study
Pietro Manuel Ferraro1, Nitin Shivappa2, Ameet Bakhai3
1Section of Nephrology, Department of Medicine, Università degli Studi di Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy. pietromanuel.ferraro@univr.it.
Insights
Hyperkalemia management in routine care often involves conservative treatment, with inconsistent guideline implementation. Recurrent hyperkalemia remains common, indicating unmet treatment goals.
Area of Science:
- Nephrology
- Internal Medicine
- Clinical Practice
Background:
- Hyperkalemia management guidelines exist, but their implementation and healthcare provider decision-making in routine clinical care are not well understood.
- Knowledge gaps persist regarding the baseline characteristics and longitudinal clinical variables of patients with hyperkalemia.
Purpose of the Study:
- To investigate the implementation of hyperkalemia guideline recommendations in clinical practice.
- To understand healthcare provider decision-making in managing hyperkalemia.
- To describe the baseline characteristics and 12-month clinical variables of patients with hyperkalemia.
Main Methods:
- An observational, prospective, longitudinal cohort study was conducted across five countries (Germany, Italy, Spain, UK, USA) from July 2022 to December 2024.
- Included were adults with recent hyperkalemia (serum potassium > 5.0 mmol/L) managed under standard of care.
- Data were collected from medical records and healthcare providers, focusing on management decisions, treatment rationale, and expectations.
Main Results:
- 1330 participants with hyperkalemia were included; 80.9% received conservative treatment, with low potassium binder use (10.8%).
- Over 12 months, 71.7% achieved normokalemia. However, among those achieving normokalemia at 9 months, recurrence by 12 months was significantly higher in recurrent (39.3%) versus incident (14.5%) cases.
- Renin-angiotensin-aldosterone system inhibitors were stopped/reduced in less than 5% of participants.
Conclusions:
- Guideline recommendations for hyperkalemia management were inconsistently implemented in clinical practice, favoring a conservative approach.
- Achieving treatment goals for hyperkalemia was frequently unmet, and hyperkalemia recurrence was common.
- Further research is needed to optimize hyperkalemia management strategies and improve patient outcomes.
Introduction:
Little is known about the implementation of guideline recommendations and healthcare provider decision-making when managing hyperkalemia. We aimed to address these knowledge gaps and better understand hyperkalemia management in routine clinical care and the baseline characteristics and longitudinal (12-month) clinical variables of participants with hyperkalemia.
Methods:
This was an observational, prospective, longitudinal, cohort study including adults with recent (≤ 21 days of enrollment) hyperkalemia (serum potassium [K+] > 5.0 mmol/L) during standard of care, across Germany, Italy, Spain, the UK, and the USA from July 2022 to December 2024. Primary and secondary data were collected from participants' medical records and their respective healthcare providers. Healthcare providers' hyperkalemia management decisions, treatment rationale, and expectations were measured overall, by incident versus recurrent cases, and by hyperkalemia severity.
Results:
In total, 1330 participants with hyperkalemia were included (458 incident, 870 recurrent). The most common treatment rationale for index hyperkalemia was ease of treatment (41.4%). Overall, 80.9% of participants received conservative treatment (no hyperkalemia treatment, monitoring K+ levels, or a low K+ diet; incident hyperkalemia 76.9%, recurrent hyperkalemia 83.2%). K+ binder use was low (10.8%) but increased with hyperkalemia severity (mild, 6.6%; moderate, 17.0%; severe 20.0%). Renin-angiotensin-aldosterone system inhibitors were stopped/reduced in < 5% of participants. Over 12 months, 71.7% of participants achieved normokalemia at any timepoint (incident 65.7%, recurrent 74.8%). Among participants with normokalemia at 9 months (incident, n = 125; recurrent, n = 294), the probability of hyperkalemia recurrence at 12 months was lower in the incident than in the recurrent group (14.5% vs 39.3%; crude odds ratio 0.26 [95% confidence interval 0.13-0.53]).
Conclusions:
Guideline recommendations for incident and recurrent hyperkalemia were inconsistently implemented in clinical practice, as demonstrated by a conservative approach to treatment. Unmet hyperkalemia treatment goals and recurrent hyperkalemia were common.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dysrhythmias VI: Management of Dysrhythmias
Antihypertensive Drugs: Potassium-Sparing Diuretics
Chronic Kidney Disease IV: Nursing Management